Altimmune, Inc. (NASDAQ:ALT) Stock Has Average Price Target of $14.33 According to Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.33.

ALT has been the topic of a number of recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Leerink Partners started coverage on Altimmune in a research report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th.

Altimmune Stock Performance

ALT opened at $3.06 on Friday. The stock has a market cap of $595.23 million, a PE ratio of -3.92 and a beta of 0.18. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average of $3.09 and a 200-day moving average of $3.08. Altimmune has a 52 week low of $2.56 and a 52 week high of $6.44.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%. Equities research analysts predict that Altimmune will post -0.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently modified their holdings of ALT. ProShare Advisors LLC boosted its position in Altimmune by 21.9% in the fourth quarter. ProShare Advisors LLC now owns 20,816 shares of the company’s stock worth $75,000 after purchasing an additional 3,735 shares during the last quarter. AXQ Capital LP increased its position in shares of Altimmune by 25.8% during the 4th quarter. AXQ Capital LP now owns 25,701 shares of the company’s stock valued at $93,000 after purchasing an additional 5,266 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Altimmune by 19.4% in the 1st quarter. Cetera Investment Advisers now owns 35,453 shares of the company’s stock worth $109,000 after purchasing an additional 5,766 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Altimmune by 26.0% in the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company’s stock worth $107,000 after buying an additional 7,167 shares during the last quarter. Finally, North Star Investment Management Corp. boosted its holdings in shares of Altimmune by 112.5% in the first quarter. North Star Investment Management Corp. now owns 17,000 shares of the company’s stock worth $52,000 after buying an additional 9,000 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biotechnology company focused on developing treatments for obesity and liver diseases. The company’s lead product candidate is pemvidutide, a dual GLP-1/glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease associated with metabolic disorders.

Altimmune’s research programs are designed to address diseases with significant unmet medical needs, including obesity-related complications and conditions involving liver inflammation and fibrosis.